Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin’s Lymphoma
Study Information
Alliance Study ID: CALGB-50201
NCT Study ID (ClinicalTrials.gov): NCT00062114
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Thomas C. Shea, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with progressive non-Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information